Otsuka Pharmaceutical Co., Ltd. / Transcend Therapeutics, Inc.
2026 · Acquisition/Merger · $1.2B · Pending
Announcement Sentiment
83
Strongly positive
Otsuka agreed to acquire Transcend Therapeutics for $700M upfront plus up to $525M in sales milestones ($1.225B total), gaining TSND-201 (methylone) for PTSD. The asset has FDA Breakthrough Therapy designation (Jul 2025), positive Phase 2 IMPACT-1 data published in JAMA Psychiatry (Feb 2026), and a Phase 3 trial enrolling patients in the U.S. On Apr 27, 2026 the FDA granted TSND-201 a National Priority Voucher in PTSD, further expediting its development. The acquisition was announced Mar 27, 2026 with an expected Q2 2026 close, subject to customary closing conditions; as of early Jun 2026 a deal close had not been publicly confirmed.